When a pharmaceutical drug has been available on the market some time, it is presupposed to go generic and the worth is meant to go down. For blockbuster arthritis drug Humira, that hasn’t occurred — till now.
AILSA CHANG, HOST:
When a drug has been available on the market for many years, it is presupposed to lose patent safety, leaving room for generics, which power the drug’s worth down. But for Humira, the blockbuster rheumatoid arthritis drug, that shift hadn’t occurred. Now, after greater than 20 years of pricing impunity, Humira is about to face cheaper competitors. NPR prescribed drugs correspondent Sydney Lupkin is right here to clarify the change. Hey, Sydney.
SYDNEY LUPKIN, BYLINE: Hey.
CHANG: OK. So what precisely is going on at present with Humira?
LUPKIN: Its first competitor has lastly launched a drug known as Amgevita. Amgevita is a biosimilar, which is sort of a generic, however not precisely. Generics are chemical copies of medicine – take into consideration lookalike blood stress tablets. Biosimilars are extra advanced. They’re variations of medicine known as biologics which can be typically antibodies or proteins. That’s what Humira is – a biologic. It’s been accepted since 2002. But with no direct competitor, its maker, AbbVie, has been capable of preserve costs excessive. And there have been dozens of worth hikes through the years. The newest one was a couple of weeks in the past, on January 3. Humira now prices round $7,000 a month earlier than insurance coverage.
CHANG: Wow. Why have not we had a Humira competitor like this till now?
LUPKIN: Well, there is a thicket of patents round Humira, and that has allowed AbbVie to keep up its monopoly. Here’s Harvard Medical School’s Ameet Sarpatwari.
AMEET SARPATWARI: You do not simply patent the lively ingredient. You can patent strategies of use. You can patent strategies of formulation. You can patent strategies of manufacture.
LUPKIN: He says many drug firms have exploited the U.S. patent system, however known as Humira the poster little one for this technique. Humira has been the best-selling pharmaceutical for some time, topping $20 billion in worldwide gross sales in 2021.
CHANG: Wait – so have all of those patents, like, blocked the FDA from approving rivals?
LUPKIN: No. Actually, the FDA has accepted seven Humira biosimilars, together with this one, however they could not launch. Amgevita received FDA approval in 2016, however there was litigation over the patents. Ultimately, there was a settlement that allowed Amgevita to launch at present. That delay got here with an enormous value, nevertheless. Harvard’s Sarpatwari labored on a research that confirmed Medicare would have saved greater than $2 billion between 2016 and 2019 if Humira biosimilars have been capable of launch once they have been accepted.
CHANG: OK. So the massive query – will this new model of Humira be any cheaper?
LUPKIN: Yes…
CHANG: OK.
LUPKIN: …But it is a little bit difficult. Amgevita will launch with two costs, in line with the drug firm that makes it, which is Amgen. One is 5% cheaper than Humira, and the opposite is 55% cheaper. If your insurer or drug advantages supervisor negotiates rebates behind the scenes, they will seemingly select the upper worth as a result of, in the event that they choose the deeper low cost, they will not get an enormous rebate. So the financial savings to start with will most likely be modest.
CHANG: So what do you assume sufferers can anticipate at, like, the pharmacy counter?
LUPKIN: The firm tells me Amgevita will not be obtainable at pharmacies for one more week or two, however do not anticipate your pharmacist to simply swap your Humira prescription over to Amgevita. Here’s Aaron Crittenden of GoodRx, a web site that helps sufferers discover prescription drug coupons.
AARON CRITTENDEN: You take into consideration the normal generic world – proper? – the place physician writes a model, and the pharmacy can simply change it over to the generic. That’s not the case right here.
LUPKIN: That’s as a result of, with biosimilars, there will be totally different guidelines, and docs will seemingly have to see huge financial savings to need to push you over to this new drug. So proper now, notably with the truth that each of them are on the identical tiers in a whole lot of profit plans, the co-pay for the affected person would be the identical. But there are anticipated to be a number of extra Humira biosimilars this summer season, and that might begin to transfer the needle on worth.
CHANG: That’s excellent news. That is NPR’s Sydney Lupkin. Thank you, Sydney.
LUPKIN: You guess.
Copyright © 2023 NPR. All rights reserved. Visit our web site phrases of use and permissions pages at www.npr.org for additional data.
NPR transcripts are created on a rush deadline by an NPR contractor. This textual content is probably not in its closing type and could also be up to date or revised sooner or later. Accuracy and availability might differ. The authoritative document of NPR’s programming is the audio document.